This is particularly relevant in ER+ breast cancers as MYC is a key factor responsible for driving the effects of estrogens on cell cycle progression and has been shown to be required for E2 dependent proliferation of ER+ breast cancer cells [38, 45, 46]. Here, ESR1 is linked to breast carcinoma.